Genprex Research Links Low TROP2 Expression to Reqorsa Resistance in Lung Cancer

• Genprex identified TROP2 expression as a potential predictor of response to its experimental Reqorsa gene therapy for non-small cell lung cancer.
• Low TROP2 expression was associated with treatment resistance in preclinical models, supported by analysis of pretreatment tumor biopsies from clinical trial patients.
• Results will be presented Nov. 18, 2026, at the EORTC-NCI-AACR Symposium in Barcelona, Spain.
• The findings could guide patient selection, but further research and prospective clinical evaluation are needed to establish TROP2's predictive value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040700PR_NEWS_USPR_____DA88008) on November 04, 2026, and is solely responsible for the information contained therein.